Vol. 1 No. 10: October
Reimbursement Reviews

Human Insulin (Entuzity KwikPen)

Published October 6, 2021

Key Messages

  • CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses human biosynthetic insulin (Entuzity KwikPen), 500 units/mL subcutaneous insulin injection, human biosynthetic, solution for injection
  • Indication: Entuzity is indicated to improve glycemic control in adults and children with diabetes mellitus requiring more than 200 units of insulin per day